Antares Pharma, Inc. (ATRS)

[jab91252]

Also, after thinking about this and re-reading my notes from the June 6, 2012 conference - I recall something about a statement that Pfizer had previously completed or conducted P1 & P2 studies a number of years ago. If I recall correctly, then that explains what CEO Wotton said about a P 3 "later this year".

Meaning that did not happen and its 6 months off or 6 months later. And I'm guessing at this point, but guessing that when Pfizer re-approached the Agency, the FDA wanted some of the pre P 3 studies done that we now know have been completed.

This P1 study:
http://www.clinicaltrials.gov/ct2/show/NCT01771822?term=5%25+gel&lead=Pfizer&rank=1

and this P1 study:
http://www.clinicaltrials.gov/ct2/show?term=5%25+gel&lead=Pfizer&rank=3

and now the latest P3 filing:
http://www.clinicaltrials.gov/ct2/show?term=5%25+gel&lead=Pfizer&rank=2